This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Spectrum Pharmaceuticals Highlights 13 Abstracts At The 55th Annual Meeting Of The American Society Of Hematology (ASH), New Orleans, Louisiana, December 7-10, 2013

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 55th Annual Meeting of the American Society of Hematology (ASH), being held in New Orleans, Louisiana, from December 7-10, 2013.

For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference website at https://ash.confex.com/ash/2013/webprogram/start.html.

 
The following are key ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use-related
abstracts being presented at the ASH meeting:
 
Abstract #       Type       Title       First Author       Date/Time
                                Location
1839 Poster P53 Based Strategy for Protection of Su Saturday, Dec. 7
Bone Marrow from Y-90 Ibritumomab 5:30 PM-7:30 PM
Tiuxetan
                                Hall G
2923 Poster Comparing The Cost-Effectiveness Of Chen Sunday, Dec. 8,
Rituximab Maintenance (MR) and 6:30 PM-8:30 PM
Radioimmunotherapy (RIT) Consolidation
Therapy Following First-Line Hall E
Chemo/Immunochemotherapies For
                Follicular Lymphoma                
3039 Poster A Single Center Phase II Trial of Samaniego Sunday, Dec. 8,

90Yttrium-Ibritumomab-Tiuxetan

6:30 PM-8:30 PM
Produces High Response Rates as First-
Line Therapy for Early Stage B Cell Hall G
Indolent Lymphoma, including Bulky
                Disease                
3350 Poster Outcomes Following Autologous Stem Cell Khouri Sunday, Dec. 8,
Transplantation (ASCT) In Patients 6:30 PM-8:30 PM
With Germinal Center B (GCB) and Non-
GCB Cell-Like Diffuse Large B Cell Hall G
Lymphomas (DLBCL) According To
Conditioning With BEAM-Rituximab
(Standard vs. High-Dose) Vs.
BEAM/Yttrium-90 Ibritumomab Tiuxetan
                (90YIT)                
369 Oral A randomized phase II study comparing Lopez-Guillermo Monday, Dec 9,
consolidation with a single dose of 10:30 AM-12:00 PM

90Y ibritumomab tiuxetan (Zevalin®)

(Z) vs. maintenance with rituximab (R) La Nouvelle
for two years in patients with newly Ballroom AB
diagnosed follicular lymphoma (FL)
responding to the regimen R-CHOP.
Preliminary results at 36 months from
                randomization                
4384 Poster Radioimmunotherapy In Ferrero Monday, Dec. 9,
Relapsed/Refractory Mantle Cell 6:00 PM-8:00 PM
Lymphoma Patients: Final Results Of a
                European MCL Network Phase II Trial               Hall G
4404 Poster Yttrium-90-Ibritumomab tiuxetan Puvvada Monday, Dec. 9,
(Zevalin) radioimmunotherapy after 6:00 PM-8:00 PM
cytoreduction with ESHAP chemotherapy
in patients with relapsed Follicular Hall G
Non-Hodgkin’s Lymphoma (NHL): Interim
                Results of a phase II study                
 
 
The following are key FOLOTYN® (pralatrexate injection) related abstracts being presented at
the ASH meeting:
                                 
Abstract #       Type       Title       First Author       Location
3044       Poster       A Phase II Study of Cyclophosphamide,       Advani       Sunday, Dec. 8,
Etoposide, Vincristine and Prednisone 6:30 PM-8:30 PM
(CEOP) Alternating with Pralatrexate
(P) as Front Line Therapy for Patients Hall G
with Peripheral T-Cell Lymphoma
(PTCL): Preliminary Results from the
                T- Cell Consortium Trial                
4284 Poster Analysis Of Peripheral T-Cell Lymphoma Carson Monday, Dec. 9,
(PTCL) Subtype By Race and 6:00 PM-8:00 PM
Geography Using The Comprehensive
Oncology Measures For Peripheral T- Hall G
Cell Lymphoma Treatment (COMPLETE)
                Dataset                
4430 Poster Pre-Clinical Analysis Of The Novel Mangone Monday, Dec. 9,
Antifolate Pralatrexate In Multiple 6:00 PM-8:00 PM
Myeloma Reveals Functional Biomarkers
                Correlated With Response               Hall G
 
The following are key Marqibo® (vinCRIStine sulfate LIPOSOME injection) related abstracts
being presented at the ASH conference:
                                 
Abstract #       Type       Title       First Author       Location
2676       Poster       High-Dose Vincristine Sulfate Liposome       Deitcher       Sunday, Dec. 8,
Injection (Marqibo(®)) Is Not 6:30 PM-8:30 PM
Associated With Clinically Meaningful
                Hematologic Toxicity               Hall E
3033 Poster Long Term Results of Vincristine Hagemeister Sunday, Dec. 8,
Sulfate Liposome Injection 6:30 PM-8:30 PM

(Marqibo ®, M) Substituted for Non-

Liposomal Vincristine in R-CHOP to Hall G
create R-CHMP in Patients with
Untreated Diffuse Large B-Cell
                Lymphoma                
4355 Poster Vincristine Sulfate Liposome Injection Kaplan Monday, Dec. 9,

(Marqibo ®) and Rituximab for

6:00 PM-8:00 PM
Patients with Relapsed and Refractory
Diffuse Large B-Cell Lymphoma or Hall G
Mantle Cell Lymphoma in Need of
                Palliative Therapy                
 

About Non-Hodgkin's Lymphoma

According to the National Cancer Institute ( www.cancer.gov), there are expected to be 69,740 new cases of non-Hodgkin's lymphoma diagnosed and approximately 19,020 deaths in the United States in 2013. Non-Hodgkin's lymphoma is defined as any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin's lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. These types can be divided into aggressive (fast-growing) and indolent or low grade (slow-growing) types, and they can be formed from either B-cells or T-cells. Prognosis and treatment depend on the stage and type of disease.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market four oncology drugs ─ FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights; and MARQIBO® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

About FOLOTYN ®

FOLOTYN, (pralatrexate injection), a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, INC. In September 2009, the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory PTCL. This indication is based on overall response rate. Clinical benefit, such as improvement in progression-free survival or overall survival, has not been demonstrated. FOLOTYN has been available to patients in the U.S. since October 2009. An updated analysis of data from PROPEL, the pivotal study of FOLOTYN in patients with relapsed or refractory PTCL, was published in the March 20, 2011 issue of the Journal of Clinical Oncology. FOLOTYN has patent protection through July 2022, based on a five-year patent term extension through the Hatch-Waxman Act.

1 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs